San Diego, United States
Encodia, with its slogan "Unlimit Biology™," is a pioneering Biotechnology firm based in the United States, founded in 2015. The company is on the forefront of proteomics innovation, developing a Next-Gen digital proteomics platform designed to make protein sequencing accessible and cost-effective. Their transformative technology utilizes a novel reverse-translation method that converts peptide sequences into DNA, which can be analyzed using Next-Generation Sequencing (NGS) devices, thereby democratizing complex proteomics research.
Encodia's last financial round was a substantial $75.00M Series C investment made on 27 January 2021. This round was supported by prominent investors such as Arch Venture Partners, GV, Biomatics Capital Partners, Tao Capital Partners, Alexandria Venture Investments, Decheng Capital, Nan Fung Life Sciences, Northpond Ventures, and Deerfield. Encodia positions itself as a key player in advancing proteomics research, offering significant opportunities for stakeholders in this burgeoning field.
Quantum-Si
